2110-19-2

Basic information

• Product Name: (S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID
• Synonyms: (S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DIHYDRO-ISOINDOL-2-YL)-BUTYRIC ACID
• CAS NO: 2110-19-2
• Molecular Formula: C13H12N2O5
• Molecular Weight: 276.24
• Mol File: 2110-19-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 599.3°Cat760mmHg
• Flash Point: 316.3°C
• Appearance: /
• Density: 1.508g/cm³
• Vapor Pressure: 3.27E-15mmHg at 25°C
• Refractive Index: 1.639
• CAS DataBase Reference: (S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID(2110-19-2)
• EPA Substance Registry System: (S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID(2110-19-2)

Safety Data

• Hazardous Substances Data: 2110-19-2(Hazardous Substances Data)

Usage

Description

(S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID is a chemical compound with potential therapeutic benefits. It features a butyric acid backbone with a carbamoyl group and an isoindol-2-yl group attached. (S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID has been studied for its potential use in treating various medical conditions, including cancer and neurological disorders, due to its ability to modulate certain biological pathways and cellular processes. Research suggests that it may have anti-tumor and anti-inflammatory properties, as well as potential neuroprotective and neurotrophic effects. Further research and development of this compound could contribute to the development of new therapeutic agents for various medical conditions.

Uses

Used in Pharmaceutical Industry:
(S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID is used as a potential therapeutic agent for the treatment of various medical conditions, such as cancer and neurological disorders, due to its ability to modulate biological pathways and cellular processes.
Used in Cancer Treatment:
(S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID is used as an anti-tumor agent for the treatment of various types of cancer. Its anti-tumor properties make it a promising candidate for further research and development in oncology.
Used in Neurological Disorder Treatment:
(S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID is used as a potential neuroprotective and neurotrophic agent for the treatment of neurological disorders. Its ability to modulate cellular processes and biological pathways may contribute to the development of new therapeutic agents for conditions such as neurodegenerative diseases and brain injuries.
Used in Anti-Inflammatory Applications:
(S)-4-CARBAMOYL-2-(1,3-DIOXO-1,3-DI HYDRO-ISOINDOL-2-YL)-BUTYRIC ACID is used as an anti-inflammatory agent, potentially beneficial in the treatment of various inflammatory conditions and diseases. Its anti-inflammatory properties may help in reducing inflammation and associated symptoms.

InChI:InChI=1/C13H12N2O5/c14-10(16)6-5-9(13(19)20)15-11(17)7-3-1-2-4-8(7)12(15)18/h1-4,9H,5-6H2,(H2,14,16)(H,19,20)

Upstream product

• 85-44-9 phthalic anhydride 
• 56-85-9 L-glutamine 
• 2614-06-4 (R)-thalidomide 
• 88-95-9 Phthaloyl dichloride 
• 56-85-9 GLUTAMINE 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 3343-28-0 N-phthaloylglutamic acid anhydride 
• 841-67-8 (S)-thalidomide 
• 25830-77-7 N-phthaloyl-L-glutamic anhydride 
• 6349-98-0 N-phthalylglutamic acid 

Downstream Products

• 64552-20-1 N²,N²-phthaloyl-glutamine-methyl ester 
• 50-35-1 thalidomide 

Relevant articles and documents

A novel strategy for efficient chemoenzymatic synthesis of D-glutamine using recombinant Escherichia coli cells

D-glutamine is a D type stereoisomer of glutamine which is involved in many metabolic processes. Seeking lower-cost and industrially scalable approaches for the synthesis of D-glutamine is very valuable both in academic career and potential applications. Herein, we developed a novel efficient chemoenzymatic strategy for producing D-glutamine. Initially, DL-glutamine was chemically prepared with cheap and accessible DL-glutamic acid as raw material. Subsequently, the L-glutamine among the racemic mixture was selectively hydrolyzed to L-glutamic acid by Escherichia coli whole-cell system which expressed L-aminopeptidase D-Ala-esterase/amidase (DmpA) from Ochrobactrum anthropi. The left D-glutamine was obtained by isoelectric point precipitation with 70% of the theoretical yield. Furthermore, we optimized enzymatic resolution conditions to determine the optimum parameters as pH 8, 30 °C, 0.1% (v/v) Triton X-100, and 1 mM Mn2+. These results suggested that our strategy might be potentially usable for the synthesis of D-glutamine in industrial productions.

Radiosynthesis of 13N-labeled thalidomide using no-carrier-added [13N]NH3

Recent studies revealed that thalidomide (1) has unique and broad pharmacological effects on multi-targets although the application of 1 in therapy is still controversial. In this study, we synthesized nitrogen-13-labeled thalidomide ([13N]1) as a potential positron emission tomography (PET) probe using no-carrier-added [13N]NH 3 as a labeling agent. By use of an automated system, [ 13N]1 was prepared by reacting N-phthaloylglutamic anhydride (2) with [13N]NH3, following by cyclization with carbonyldiimidazole in a radiochemical yield of 56±12% (based on [ 11N]NH3, corrected for decay) and specific activity of 49±24GBq/μmol at the end of synthesis (EOS). At EOS, 570-780MBq (n=7) of [13N]1 was obtained at a beam current of 15 μA after 15 min proton bombardment with a synthesis time of 14 min from the end of bombardment. Using a small animal PET scanner, preliminary biodistribution of [ 13N]1 in mice was examined. Copyright

AN IMPROVED PROCESS FOR THE PREPARATION OF THALIDOMIDE

An improved process for the preparation of Thalidomide a TNF-alpha inhibitor by the conversion of N-phthaloyl L-glutamine in presence of an active ingredient of inorganic acid salts such as 1,1-Carbonyldi(1,2,4-triazole) as a condensing agent.